Cargando…
High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy
BACKGROUND. This study characterizes the tumor‐immune microenvironment in pretreatment, localized anal squamous cell carcinoma (ASCC), including two markers that have not previously been studied in ASCC: indoleamine 2,3 dioxygenase 1 (IDO1) and human leukocyte antigen (HLA) class I. MATERIALS AND ME...
Autores principales: | Mitra, Devarati, Horick, Nora K., Brackett, Diane G., Mouw, Kent W., Hornick, Jason L., Ferrone, Soldano, Hong, Theodore S., Mamon, Harvey, Clark, Jeffrey W., Parikh, Aparna R., Allen, Jill N., Ryan, David P., Ting, David T., Deshpande, Vikram, Wo, Jennifer Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656510/ https://www.ncbi.nlm.nih.gov/pubmed/30755500 http://dx.doi.org/10.1634/theoncologist.2018-0794 |
Ejemplares similares
-
Combined PET-CT and MRI for response evaluation in patients with squamous cell anal carcinoma treated with curative-intent chemoradiotherapy
por: Adusumilli, Pratik, et al.
Publicado: (2022) -
ESGAR consensus statement on the imaging of fistula-in-ano and other causes of anal sepsis
por: Halligan, S., et al.
Publicado: (2020) -
Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution
por: Holliday, Emma B, et al.
Publicado: (2022) -
Magnetization transfer imaging to assess tumour response after chemoradiotherapy in rectal cancer
por: Martens, Milou H, et al.
Publicado: (2015) -
Diffusion-weighted imaging complements T2-weighted MRI for tumour response assessment in squamous anal carcinoma
por: Prezzi, Davide, et al.
Publicado: (2023)